Brain atrophy and demyelination in MOGAD, AQP4+NMOSD and seronegative NMOSD

被引：0
|
作者：
Hagbohm, Caroline [1 ,2 ]
Ouellette, Russell [1 ,2 ]
Jonsson, Dagur Ingi [2 ,3 ]
Iacobaeus, Ellen [2 ,4 ]
Granberg, Tobias [1 ,2 ]
机构：
[1] Karolinska Univ Hosp, Dept Neuroradiol, Stockholm, Sweden
[2] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Neurophysiol, Stockholm, Sweden
[4] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1447/2506
引用
收藏
页码：920 / 920
页数：1
相关论文
共 50 条
  • [21] Switching from rituximab to eculizumab in patients with AQP4+NMOSD in the United States: Impact on hospitalisations and comorbidities
    Lee, Justin
    Kielhorn, Adrian
    Fam, Sami
    Riser, Emily
    Flanagan, Eoin
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 391 - 392
  • [22] Predicting time to serologic diagnosis of AQP4+NMOSD based on clinical factors and social determinants of health
    Rotstein, Dalia L.
    Freedman, Mark S.
    Lee, Liesly
    Marrie, Ruth Ann
    Morrow, Sarah A.
    Mccombe, Jennifer A.
    Parks, Natalie E.
    Smyth, Penelope
    Konig, Andrea
    Vyas, Manav V.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 83
  • [23] Eculizumab in AQP4-IgG NMOSD
    Marignier, Romain
    Kunchok, Amy
    NEUROLOGY, 2024, 103 (09)
  • [24] Differential mri biomarkers between mogad, aqp4-nmosd and rrms: a magnims multicenter study
    Cortese, R.
    Battaglini, M.
    Prados, F.
    Bianchi, A.
    Haider, L.
    Kappos, L.
    Yaldizli, Oe.
    Mueller, J.
    Lukas, C.
    Bellenberg, B.
    Schneider, R.
    Groppa, S.
    Grothe, M.
    Liu, Y.
    Duan, Y.
    Llufriu, S.
    Sepulveda, M.
    Arrambide, G.
    Sastre-Garriga, J.
    Rovira, A.
    Paul, F.
    Wuerfel, J.
    Jacob, A.
    Barkhof, F.
    De Stefano, N.
    Ciccarelli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 455 - 456
  • [25] Complement Activation Fragments C3a, C4a and C5a in Cerebrospinal Fluid of Patients with Tumefactive MS Lesions and Comparison with MOGAD and AQP4+NMOSD
    Gilligan, Michael
    Overlee, Brittany
    Tobin, Oliver
    Thakolwiboon, Smathorn
    Sagen, Jessica
    Fryer, James
    Willrich, Maria A. V.
    Chen, John
    Flanagan, Eoin
    Howe, Charles
    Pittock, Sean
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1171 - 1171
  • [26] The difference of intercellular cytokine profiles among MOG+CNS disorders, AQP4+NMOSD, and MS patients
    Liu, J.
    Mori, M.
    Sugimoto, K.
    Uzawa, A.
    Uchida, T.
    Masuda, H.
    Ohtani, R.
    Isose, S.
    Arai, K.
    Kuwabara, S.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 836 - 836
  • [27] Impact Of Eculizumab On Hospitalization Rates And Relapse Treatment In Patients With AQP4+NMOSD: The Phase 3 PREVENT Study
    Kim, H.
    Pittock, S.
    Berthele, A.
    Fujihara, K.
    Levy, M.
    Palace, J.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K.
    Pace, A.
    Fujita, K. P.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 105 - 105
  • [28] C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD
    Pache, Florence
    Ringelstein, Marius
    Aktas, Orhan
    Kleiter, Ingo
    Jarius, Sven
    Siebert, Nadja
    Bellmann-Strobl, Judith
    Paul, Friedemann
    Ruprecht, Klemens
    JOURNAL OF NEUROIMMUNOLOGY, 2021, 360
  • [29] The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
    Roca-Fernandez, A.
    Camera, V
    Loncarevic-Whitaker, G.
    Messina, S.
    Mariano, R.
    Vincent, A.
    Sharma, S.
    Leite, M., I
    Palace, J.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (04)
  • [30] The landscape of PBMCs in AQP4-IgG seropositive NMOSD and MOGAD, assessed by high dimensional mass cytometry
    Yao, Mengyuan
    Wang, Wenjing
    Sun, Jiali
    Guo, Tianshu
    Bian, Jiangping
    Xiao, Fuyao
    Li, Yuanyuan
    Cong, Hengri
    Wei, Yuzhen
    Zhang, Xinghu
    Liu, Jianghong
    Yin, Linlin
    CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (02)
12345